CLINICAL TRIALS PROFILE FOR XOPENEX HFA
✉ Email this page to a colleague
All Clinical Trials for Xopenex Hfa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00124176 ↗ | Continuous Levalbuterol for Treatment of Status Asthmaticus in Children | Completed | Sunovion | Phase 4 | 2004-04-01 | This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol. |
| NCT00124176 ↗ | Continuous Levalbuterol for Treatment of Status Asthmaticus in Children | Completed | Children's Hospital of Philadelphia | Phase 4 | 2004-04-01 | This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol. |
| NCT00500578 ↗ | Intermittent Use of Aerosolized Ribavirin for Treatment of RSV | Completed | ICN Pharmaceuticals | Phase 4 | 2003-02-01 | Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding. |
| NCT00500578 ↗ | Intermittent Use of Aerosolized Ribavirin for Treatment of RSV | Completed | M.D. Anderson Cancer Center | Phase 4 | 2003-02-01 | Primary Objectives: 1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia. 2. To determine the effect of this regimen on persistence of viral shedding. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Xopenex Hfa
Condition Name
Clinical Trial Locations for Xopenex Hfa
Trials by Country
Clinical Trial Progress for Xopenex Hfa
Clinical Trial Phase
Clinical Trial Sponsors for Xopenex Hfa
Sponsor Name
